Clover Health Investments Corp

CLOV is entrenched in a Stage 4 decline with a clear series of lower highs and lows; medium-term bias remains bearish, and the current pullback into the downward-sloping 9/21 EMA zone offers a favorable point to initiate selling. Long-term uptrend is intact above major moving averages but is secondary to the prevailing bearish regime.

• ↑51% YoY membership growth to 156K members in Q1 2026
• ↑Revenue surged 62% YoY to $749M with $160M gross profit
• ↓Extremely high volatility implies wide share-price swings